Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Metastasis | Research article

The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice

Authors: Krzysztof Kaliszewski, Dorota Diakowska, Łukasz Nowak, Beata Wojtczak, Jerzy Rudnicki

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Papillary thyroid cancer (PTC) is unique among cancers in that patient age is a consideration in staging. One of the most important modifications in the 8th Edition of the American Joint Committee on Cancer (AJCC) classification is to increase the age cut off for risk stratification in PTC from 45 to 55 years. However, whether this cut off is useful in clinical practice remains controversial. In the present study, we assessed how well this new age threshold stratifies patients with aggressive PTC.

Methods

We retrospectively analyzed the clinicopathological features and overall survival rate of patients with PTC admitted to and surgically treated at a single surgical center. The study protocol was divided into two series. In each series all patients (n = 523) were divided in 2 groups according to age cut off. In the first series (cut off 45) patients < 45 (n = 193) vs. ≥45 (n = 330) were compared, and in the second series (cut off 55) patients < 55 (n = 306) vs. ≥55 (n = 217) were compared.

Results

The rate of the prevalence of locally advanced disease (pT3 and pT4) was significantly higher in the patients above 55 years old than in those below 55 years old (p = 0.013). No significant differences were found for this parameter in series with cut off point 45 years old. A significantly higher risk of locally advanced disease T3 + T4 (OR = 4.87) and presence of LNM (N1) (OR = 3.78) was observed in ≥45 years old group (p = 0.021 and p < 0.0001, respectively). More expressive results were found for the patients ≥55 years old group, where the risk of locally advanced disease (T3 + T4) was higher (OR = 5.21) and LNM presence was OR = 4.76 (p < 0.001 and p < 0.0001, respectively). None of the patients below 55 years old showed distant metastasis, but 19 patients above 55 years old showed M1 (p < 0.0001). In older patients group (≥55 years old) we observed deaths related thyroid cancer in 11 individuals.

Conclusions

The age cut off of 55 years old for risk stratification proposed by the 8th Edition of AJCC effectively stratifies PTC patients with a poor prognosis, indicating it is likely to be useful in clinical practice.
Literature
1.
go back to reference Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-Cancer epidemic? The increasing impact of Overdiagnosis. N Engl J Med. 2016;375:614–7.CrossRef Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-Cancer epidemic? The increasing impact of Overdiagnosis. N Engl J Med. 2016;375:614–7.CrossRef
2.
go back to reference Zambeli-Ljepovic A, Wang F, Dinan MA, Hyslop T, Roman SA, Sosa JA, Scheri RP. Low-risk thyroid Cancer in elderly: Total thyroidectomy/RAI predominates but lacks survival advantage. J Surg Res. 2019;243:189–97.CrossRef Zambeli-Ljepovic A, Wang F, Dinan MA, Hyslop T, Roman SA, Sosa JA, Scheri RP. Low-risk thyroid Cancer in elderly: Total thyroidectomy/RAI predominates but lacks survival advantage. J Surg Res. 2019;243:189–97.CrossRef
3.
go back to reference Englum BR, Pura J, Reed SD, Roman SA, Sosa JA, Scheri RP. A bedside risk calculator to preoperatively distinguish follicular thyroid carcinoma from follicular variant of papillary thyroid carcinoma. World J Surg. 2015;39:2928–34.CrossRef Englum BR, Pura J, Reed SD, Roman SA, Sosa JA, Scheri RP. A bedside risk calculator to preoperatively distinguish follicular thyroid carcinoma from follicular variant of papillary thyroid carcinoma. World J Surg. 2015;39:2928–34.CrossRef
4.
go back to reference Oyer SL, Fritsch VA, Lentsch EJ. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients. Ann Otol Rhinol Laryngol. 2014;123:94–100.CrossRef Oyer SL, Fritsch VA, Lentsch EJ. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients. Ann Otol Rhinol Laryngol. 2014;123:94–100.CrossRef
5.
go back to reference Longheu A, Medas F, Pisano G, Gordini L, Nicolosi A, Sorrenti S, Erdas E, Calò PG. Differentiated thyroid cancer in patients ≥75 years: histopathological features and results of surgical treatment. Int J Surg. 2016;33(Suppl 1):S159–63.CrossRef Longheu A, Medas F, Pisano G, Gordini L, Nicolosi A, Sorrenti S, Erdas E, Calò PG. Differentiated thyroid cancer in patients ≥75 years: histopathological features and results of surgical treatment. Int J Surg. 2016;33(Suppl 1):S159–63.CrossRef
6.
go back to reference Kim ES, Lee Y, Seo H, Son GS, Kwon SY, Kim YS, Seo JA, Kim NH, Suh SI, Ryoo I, You SH. Clinical features of recently diagnosed papillary thyroid carcinoma in elderly patients aged 65 and older based on 10 years of sonographic experience at a single institution in Korea. Ultrasonography. 2017;36:355–62.CrossRef Kim ES, Lee Y, Seo H, Son GS, Kwon SY, Kim YS, Seo JA, Kim NH, Suh SI, Ryoo I, You SH. Clinical features of recently diagnosed papillary thyroid carcinoma in elderly patients aged 65 and older based on 10 years of sonographic experience at a single institution in Korea. Ultrasonography. 2017;36:355–62.CrossRef
7.
go back to reference Kazaure HS, Roman SA, Sosa JA. The impact of age on thyroid cancer staging. Curr Opin Endocrinol Diabetes Obes. 2018;25:330–4.CrossRef Kazaure HS, Roman SA, Sosa JA. The impact of age on thyroid cancer staging. Curr Opin Endocrinol Diabetes Obes. 2018;25:330–4.CrossRef
8.
go back to reference Yan H, Winchester DJ, Prinz RA, Wang CH, Nakazato Y, Moo-Young TA. Differences in the impact of age on mortality in well-differentiated thyroid Cancer. Ann Surg Oncol. 2018;25:3193–9.CrossRef Yan H, Winchester DJ, Prinz RA, Wang CH, Nakazato Y, Moo-Young TA. Differences in the impact of age on mortality in well-differentiated thyroid Cancer. Ann Surg Oncol. 2018;25:3193–9.CrossRef
9.
go back to reference Huang TW, Lai JH, Wu MY, Chen SL, Wu CH, Tam KW. Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. BMC Med. 2013;11:191.CrossRef Huang TW, Lai JH, Wu MY, Chen SL, Wu CH, Tam KW. Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. BMC Med. 2013;11:191.CrossRef
10.
go back to reference Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–60.PubMedPubMedCentral Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–60.PubMedPubMedCentral
11.
go back to reference Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin. 2013;63:374–94.CrossRef Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin. 2013;63:374–94.CrossRef
12.
go back to reference Singhal S, Sippel RS, Chen H, Schneider DF. Distinguishing classical papillary thyroid microcancers from follicular-variant microcancers. J Surg Res. 2014;190:151–6.CrossRef Singhal S, Sippel RS, Chen H, Schneider DF. Distinguishing classical papillary thyroid microcancers from follicular-variant microcancers. J Surg Res. 2014;190:151–6.CrossRef
13.
go back to reference Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;68:55–63.CrossRef Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;68:55–63.CrossRef
14.
go back to reference Yu L, Hong H, Han J, Leng SX, Zhang H, Yan X. Comparison of survival and risk factors of differentiated thyroid Cancer in the geriatric population. Front Oncol. 2020;10:42.CrossRef Yu L, Hong H, Han J, Leng SX, Zhang H, Yan X. Comparison of survival and risk factors of differentiated thyroid Cancer in the geriatric population. Front Oncol. 2020;10:42.CrossRef
15.
go back to reference Banerjee M, Muenz DG, Chang JT, Papaleontiou M, Haymart MR. Tree-based model for thyroid cancer prognostication. J Clin Endocrinol Metab. 2014;99:3737–45.CrossRef Banerjee M, Muenz DG, Chang JT, Papaleontiou M, Haymart MR. Tree-based model for thyroid cancer prognostication. J Clin Endocrinol Metab. 2014;99:3737–45.CrossRef
16.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRef
17.
go back to reference Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–09.CrossRef Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–09.CrossRef
18.
go back to reference Xu B, Tallini G, Scognamiglio T, Roman BR, Tuttle RM, Ghossein RA. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:512–7.CrossRef Xu B, Tallini G, Scognamiglio T, Roman BR, Tuttle RM, Ghossein RA. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:512–7.CrossRef
19.
go back to reference Jug R, Jiang X. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: an evidence-based nomenclature change. Pathol Res Int. 2017;2017:1057252.CrossRef Jug R, Jiang X. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: an evidence-based nomenclature change. Pathol Res Int. 2017;2017:1057252.CrossRef
20.
go back to reference Kuo EJ, Roman SA, Sosa JA. Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery. 2013;154:1246–53.CrossRef Kuo EJ, Roman SA, Sosa JA. Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery. 2013;154:1246–53.CrossRef
21.
go back to reference Lerner J, Goldfarb M. Follicular variant papillary thyroid carcinoma in a pediatric population. Pediatr Blood Cancer. 2015;62:1942–6.CrossRef Lerner J, Goldfarb M. Follicular variant papillary thyroid carcinoma in a pediatric population. Pediatr Blood Cancer. 2015;62:1942–6.CrossRef
22.
go back to reference Zhou P, Tian S, Li J, Zhao Y, Liu W, Zhang Y, Hu Z. Paradoxes in thyroid carcinoma treatment: analysis of the SEER database 2010–2013. Oncotarget. 2017;8:345–53.CrossRef Zhou P, Tian S, Li J, Zhao Y, Liu W, Zhang Y, Hu Z. Paradoxes in thyroid carcinoma treatment: analysis of the SEER database 2010–2013. Oncotarget. 2017;8:345–53.CrossRef
23.
go back to reference Moten AS, Zhao H, Willis AI. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients. Surg Oncol. 2019;29:184–9.CrossRef Moten AS, Zhao H, Willis AI. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients. Surg Oncol. 2019;29:184–9.CrossRef
24.
go back to reference Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34.CrossRef Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34.CrossRef
25.
go back to reference Schneider DF, Elfenbein D, Lloyd RV, Chen H, Sippel RS. 2015 lymph node metastasis do not impact survival in follicular variant papillary thyroid cancer. Ann Surg Oncol. 2015;22:158–63.CrossRef Schneider DF, Elfenbein D, Lloyd RV, Chen H, Sippel RS. 2015 lymph node metastasis do not impact survival in follicular variant papillary thyroid cancer. Ann Surg Oncol. 2015;22:158–63.CrossRef
26.
go back to reference Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144:1070–8.CrossRef Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144:1070–8.CrossRef
27.
go back to reference Jeon MJ, Kim WG, Kim TH, Kim HK, Kim BH, Yi HS, Kim ES, Kim H, Kim YN, Kim EH, Kim TY, Kim SW, Kang HC, Chung JH, Shong YK, Kim WB. Korean thyroid Cancer study group 2017 disease-specific mortality of differentiated thyroid Cancer patients in Korea: a multicenter cohort study. Endocrinol Metab (Seoul). 2017;32:434–41.CrossRef Jeon MJ, Kim WG, Kim TH, Kim HK, Kim BH, Yi HS, Kim ES, Kim H, Kim YN, Kim EH, Kim TY, Kim SW, Kang HC, Chung JH, Shong YK, Kim WB. Korean thyroid Cancer study group 2017 disease-specific mortality of differentiated thyroid Cancer patients in Korea: a multicenter cohort study. Endocrinol Metab (Seoul). 2017;32:434–41.CrossRef
28.
go back to reference Zhang S, Jiang XH. 2018 clinical features of papillary thyroid carcinoma patients associated with lateral lymph node metastasis in different ages. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018;32:1319–24.PubMed Zhang S, Jiang XH. 2018 clinical features of papillary thyroid carcinoma patients associated with lateral lymph node metastasis in different ages. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018;32:1319–24.PubMed
29.
go back to reference De Castro TP, Waissmann W, Simoes TC, de Mello RC, Carvalho DP. Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study. Clin Endocrinol. 2016;85:466–74.CrossRef De Castro TP, Waissmann W, Simoes TC, de Mello RC, Carvalho DP. Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study. Clin Endocrinol. 2016;85:466–74.CrossRef
30.
go back to reference Gillanders SL, O'Neill JP. Prognostic markers in well differentiated papillary and follicular thyroid cancer (WDTC). Eur J Surg Oncol. 2018;44:286–96.CrossRef Gillanders SL, O'Neill JP. Prognostic markers in well differentiated papillary and follicular thyroid cancer (WDTC). Eur J Surg Oncol. 2018;44:286–96.CrossRef
31.
go back to reference Orosco RK, Hussain T, Brumund KT, Oh DK, Chang DC, Bouvet M. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the surveillance, epidemiology, and end results database. Thyroid. 2015;25:125–32.CrossRef Orosco RK, Hussain T, Brumund KT, Oh DK, Chang DC, Bouvet M. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the surveillance, epidemiology, and end results database. Thyroid. 2015;25:125–32.CrossRef
32.
go back to reference Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, Sywak M, Eskander AE, Freeman JL, Campbell MJ, Shen WT, Vaisman F, Momesso D, Corbo R, Vaisman M, Shaha A, Tuttle RM, Shah JP, Patel SG. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25:1106–14.CrossRef Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, Sywak M, Eskander AE, Freeman JL, Campbell MJ, Shen WT, Vaisman F, Momesso D, Corbo R, Vaisman M, Shaha A, Tuttle RM, Shah JP, Patel SG. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25:1106–14.CrossRef
Metadata
Title
The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice
Authors
Krzysztof Kaliszewski
Dorota Diakowska
Łukasz Nowak
Beata Wojtczak
Jerzy Rudnicki
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07636-0

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine